Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market.Novo Nordisk’s Legal Move ExplainedNovo Nordisk, in its press release, said Hims & Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.Hims c ...

Shield shares jump after FDA extends Accrufer exclusivity Proactive uses images sourced from Shutterstock Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) jumped as much 11% earlier in the session after the company said US regulators had granted an additional three years of data exclusivity for its oral iron therapy Accrufer. The AIM-listed pharmaceuticals group said the US Food and Drug Admin ...

Market Overview - US stocks experienced a positive turn on Monday, with the Dow Jones Industrial Average closing above 50,000 for the first time, while the S&P 500 and Nasdaq Composite both rose approximately 0.5% [1] - The market remains cautious as investors await significant earnings reports and economic data releases later in the week [1][4] Software Sector - The software sector is under scrutiny due to concerns about AI disruption, highlighted by a significant drop in shares of Monday.com, which fell as much as 23% after providing disappointing revenue and profit guidance [2][8] - Monday.com reported adjusted earnings per share of $1.04 for the fourth quarter, exceeding estimates, but its first-quarter revenue guidance of $338 million to $340 million fell short of expectations [14][15][16] Economic Data - Investors are anticipating the delayed January jobs report from the Bureau of Labor Statistics, with a focus on potential signs of weakness in the labor market following a disappointing ADP payrolls update [4] Earnings Reports - ON Semiconductor is set to release its earnings results after the market close on Monday, with other major companies like Coca-Cola, McDonald's, and Cisco expected to report later in the week [5] Kroger Leadership Change - Kroger's stock surged over 8% after announcing the appointment of former Walmart executive Greg Foran as CEO, as the company aims to increase market share following a blocked acquisition of Albertsons [5][6] STMicroelectronics and Amazon Partnership - STMicroelectronics announced a multiyear, multibillion-dollar deal with Amazon to supply chips for AWS data centers, resulting in an 8% increase in STMicroelectronics' stock [9][10] - This partnership is part of STMicroelectronics' strategy to enhance its position in the AI market and reduce reliance on other sectors [10][11] Cryptocurrency and Gold - Bitcoin fell below $70,000 after experiencing significant volatility, while gold futures rose above $5,000 an ounce as dip-buyers returned to the market [3][21][22]

分组1 - Hims and Hers announced a GLP-1 drug comparable to Novo Nordisk's, prompting a swift response from the FDA [2][3] - Novo Nordisk's oral semaglutide utilizes a patented technology acquired from Emisphere for drug absorption [4][5] - Hims and Hers claimed to have developed a different absorption technology using a liposomal formulation, which raises concerns about the drug's approval status [6][10] 分组2 - The FDA referred the case to the DOJ, indicating potential legal action, which is unusual for initial enforcement [6][8] - The FDA's involvement suggests serious concerns regarding the safety and efficacy of Hims and Hers' unapproved drug [10][15] - Hims and Hers has a history of aggressive market strategies, but their compliance with regulations is questioned [11][12] 分组3 - Novo Nordisk is expected to remain in the market with compounded formulations, but selling the new pill is doubtful due to regulatory challenges [13][14][15] - The competitive landscape includes other companies like Lilly, which are also exploring direct-to-consumer models [17][18] - Hims and Hers' reputation may hinder partnerships with pharmaceutical companies, impacting their market position [20]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Wegovy and Ozempic maker Novo Nordisk filed a lawsuit against Hims & Hers as it seeks a ban on the telehealth provider offering copycat versions of its weight-loss and obesity medications https://t.co/4ebA8AHWRN ...

Market Overview - U.S. stock futures indicate a mixed to slightly lower open as investors digest a volatile end to the previous week and anticipate crucial economic data releases [1] - Major U.S. index futures show slight downward pressure, with Nasdaq 100 futures down approximately 0.5%, S&P 500 futures down around 0.3%, and Dow Jones Industrial Average futures indicating a 0.1% decline [2] - The broader market sentiment is influenced by a rotation out of technology and software stocks into more cyclical and "old economy" sectors due to concerns over AI disruption [3] Upcoming Economic Data - The delayed January jobs report is expected to show a gain of approximately 55,000 jobs, while the January Consumer Price Index (CPI) report will provide crucial information regarding inflation trends [4] Corporate Earnings Reports - Major companies set to release earnings reports include Coca-Cola, Datadog, Ford Motor, Robinhood, Lyft, McDonald's, CVS Health, Shopify, Coinbase, Rivian, and Pinterest [5] Individual Stock Movements - Eli Lilly shares surged over 2% following the announcement of a definitive agreement to acquire Orna Therapeutics for up to $2.4 billion [6] - Kroger stock advanced around 5% after reports of naming former Walmart executive Greg Foran as its new CEO [6] - Novo Nordisk shares rose over 7% after Hims & Hers Health announced it would stop offering a copycat version of Wegovy, leading to a significant drop in Hims & Hers stock [6] - Transocean announced it will acquire Valaris in an all-stock deal valued at $5.8 billion, with Transocean shares down 4% and Valaris shares up 14.6% in premarket trading [6] Commodities and Bonds - Gold futures are slightly higher, trading just above $5,000 an ounce, while Silver futures are up 3% to about $79.50 an ounce [7] - West Texas Intermediate (WTI) crude futures increased to $63.65 a barrel, and the yield on the 10-year Treasury note rose to nearly 4.24% [7] Notable Stock News - Nvidia and Caterpillar saw significant gains of 8% and 7% respectively on Friday, but both are pointing lower in premarket trading [10] - Amazon stock declined over 5.5% on Friday and is down another 0.4% in premarket [10] - Dynatrace surged over 13% in premarket trading ahead of its earnings report [10] - U.S.-listed shares of STMicroelectronics jumped 6.5% on news of an expanded partnership with Amazon Web Services [10] - Cryptocurrency-tied stocks such as MARA Holdings, MicroStrategy, and Coinbase are down between 2.5% and 5% in premarket after a volatile weekend for Bitcoin [10]

Under new drug-review rules, decisions at the FDA risk becoming more opaque, arbitrary or even politically motivated—making it far harder for pharma companies and their investors to model and plan https://t.co/UIkuRfRZNW ...

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although down 7% year-over-year on both reported and constant currency basis [1][3] Financial Performance - The company achieved nearly $1 billion in revenue from its products LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, reflecting strong execution and financial discipline [2] - For fiscal 2026, Biogen expects earnings between $15.25 and $16.25 per share, above the consensus estimate of $14.92, but anticipates a mid-single-digit revenue decline compared to 2025 due to expected declines in Multiple Sclerosis product revenue, partially offset by growth in other areas [3] Market Reaction - Following the earnings announcement, Biogen shares fell 0.9% to $199.40 in pre-market trading [3] - Analysts have adjusted their price targets for Biogen, with Piper Sandler maintaining a Neutral rating and raising the target from $157 to $177, HC Wainwright & Co. maintaining a Buy rating and increasing the target from $194 to $228, and Wedbush maintaining a Neutral rating with a target increase from $178 to $187 [4]

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although down 7% year-over-year [1][3] Financial Performance - The company generated nearly $1 billion in revenue from its drugs LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, reflecting strong execution and financial discipline [2] - For fiscal 2026, Biogen expects earnings between $15.25 and $16.25 per share, above the consensus estimate of $14.92, but anticipates a mid-single-digit revenue decline compared to 2025 due to expected declines in Multiple Sclerosis product revenue [3] Stock Performance and Analyst Ratings - Following the earnings announcement, Biogen shares fell 0.9% to $199.40 in pre-market trading [3] - Analysts have adjusted their price targets for Biogen, with Piper Sandler maintaining a Neutral rating and raising the target from $157 to $177, HC Wainwright & Co. maintaining a Buy rating and increasing the target from $194 to $228, and Wedbush maintaining a Neutral rating with a target increase from $178 to $187 [4]